21 matches for your search in the start-up spotlight
rss
Multi-dimensional program to build local research capability and startup ecosystem as well as joint R&D projects
31-May-2024
Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Technology (KAIST). The academia-industry cooperation aims at advancing the research and development ecosystem in South Korea for industrial ...
Partnerships with BenevolentAI and Exscientia to drive accelerated drug discovery with higher probability of success
20-Sep-2023
Merck announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts. The partnerships, with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., ...
Both companies to accelerate development and manufacturing of viral vector-based gene therapy applications
15-Dec-2022
Merck has signed a non-binding Memorandum of Understanding (MoU) with Synplogen, a startup spun out of Kobe University's Graduate School of Science, Technology and Innovation. Both companies aim to integrate their capabilities to provide streamlined development, manufacturing and testing for ...
09-Jun-2022
Proxygen announced that the company has entered into a strategic multi-year research collaboration and license agreement with Merck. Proxygen is eligible to receive up to€495 million ($554 million at the average USD/EUR FX rate of Q1 2022)in continuous R&D funding, upfront and success-based ...
Recombinant protein has the potential to accelerate ischemic and hemorrhagic stroke recovery
24-Jan-2022
Merck announced that Elevian has been selected as the North American winner of its 2021 Advance Biotech Grant Program. The early-stage biotechnology company, which is based in Allston, Massachusetts, USA, was selected for its innovative recombinant protein, which has the potential to accelerate ...
Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics
22-Dec-2021
Merck announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Merck entered into an agreement to secure the global ...
“Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”
09-Dec-2021
Merck announced the expansion of its strategic, corporate venture capital arm M Ventures. The new investment of €600 million allocated to M Ventures will be deployed over the next five years. This is the third increase in financial commitment announced by Merck since the creation of M Ventures ...
12-Jul-2021
Merck, a leading science and technology company, today announced a second collaboration agreement in its Bioelectronics innovation field with Innervia Bioelectronics, a start-up and subsidiary of Inbrain Neuroelectronics S.L., Barcelona, Spain. The aim of the collaboration is to co-develop the ...
Platform combined with virotherapy targets cancerous cells while protecting healthy tissue of key organs
21-Oct-2020
Merck announced that Combined Therapeutics Inc., Cambridge, Massachusetts, USA, has been selected as the North American winner of its 2020 Advance Biotech Grant Program. The biotechnology company was selected for its innovative nucleic acid platform which, combined with virotherapy, has the ...
Startup from Merck Innovation Lab in Israel Markets First Predictive Maintenance Sensors
25-Jun-2020
Merck announced the first commercial product from Feelit, based in Haifa, Israel. Feelit is an Industry 4.0 startup that was part of the Merck PMatX innovation lab for next-generation electronics in Israel. RetroFeel™, the company’s first product, combines a wireless edge device and a printed ...
